Patient demographics

All PatientsWHO IIWHO IIIWHO IV
No. of patients
    Total90242640
    Presurgery43 (47.8%)15 (62.5%)15 (57.7%)13 (32.5%)
    Postsurgery, pretreatment15 (16.7%)5 (20.8%)3 (12.0%)7 (17.5%)
    On treatment (radiation, chemotherapy, and so forth)32 (35.6%)4 (16.7%)8 (32.0%) (2 on bevacizumab)20 (50.0%) (2 on bevacizumab)
Age (yr)
    Mean50.34446.356.8
    Range15 (pediatric)–9022–9015 (pediatric)–7019–81
Sex
    Male59 (65.6%)10 (41.7%)17 (65.4%)32 (80.0%)
    Female31 (35.4%)14 (58.3%)9 (34.6%)8 (20.0%)
IDH status
    Wild-type51 (56.7%)2 (8.3%)11 (42.3%)38 (95.0%)
    Mutant39 (43.3%)22 (91.7%)15 (57.7%)2 (5.0%)
MGMT-promoter methylation status
    Unmethylated27 (30.0%)1 (4.2%)6 (23.1%)20 (50.0%)
    Methylated17 (18.9%)4 (16.7%)1 (3.8%)12 (30.0%)
    NA46 (51.1%)19 (79.2%)19 (73.1%)8 (20.0%)
Histology
    Astrocytoma25 (27.8%)10 (41.7%)15 (57.7%)NA
    Oligoastrocytoma11 (12.2%)2 (8.3%)9 (34.6%)NA
    Oligodendroglioma14 (15.6%)12 (50.0%)2 (7.7%)NA
  • Note:—NA indicates not applicable.

  • a Data are number and percentage unless otherwise indicated.